Skip to content

Pseudohypoparathyroidism Type 1c C2932716

Published: July 22, 2026Updated: August 27, 2026

A rare genetic disorder where the body doesn't respond to parathyroid hormone, causing low calcium and high phosphate levels. It can cause short stature, bone abnormalities, and developmental issues. Treatment involves calcium and vitamin D supplements to manage symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
E34.9
ICD-11
5A00.0
Body system
endocrine
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Muscle cramps (tetany) due to hypocalcemia

Fatigue or weight changes

(endocrine)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Short stature (growth deficiency)

(endocrine)

Subcutaneous ossifications (hard nodules)

(endocrine)

Intellectual disability

(endocrine)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Calcium and active vitamin D therapy

Calcitriol and calcium supplementation form the cornerstone of PHP1c management, correcting hypocalcemia and reducing the risk of seizures and other complications from PTH resistance.

medication
2

Endocrine management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Comprehensive mineral panel monitoring

Regular monitoring of calcium, phosphorus, magnesium, 25-hydroxyvitamin D, and PTH levels enables precise adjustment of therapeutic interventions.

monitoring

Additional treatment options

Thiazide diuretics for hypercalciuria

Thiazide diuretics help reduce excessive urinary calcium excretion, a common feature in PHP1c, and assist in maintaining stable serum calcium levels when combined with standard supplementation.

medication

Phosphorus-restricted diet

Limiting dietary phosphorus intake helps address hyperphosphatemia and supports the action of vitamin D therapy in restoring mineral balance.

dietary

Psychological support and developmental assessment

PHP1c is associated with Albright hereditary osteodystrophy features including potential cognitive impacts. Psychological evaluation and appropriate support services address emotional well-being and developmental needs.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Pseudohypoparathyroidism Type 1c C2932716?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Mantovani G, Spada A, Bastepe M. Pseudohypoparathyroidism: Genetics, Cardiovascular Disease, and Targeted Therapeutic Approaches. Endocr Rev. 2022.

review2022
2

Bilezikian JP, Modi N, Chang W, et al. Endocrine Society Clinical Practice Guideline: Management of Hypoparathyroidism and Pseudohypoparathyroidism. J Clin Endocrinol Metab. 2023.

guideline2023
3

Germain-Lee EL, Groman P, Juppner H, et al. Long-term Outcomes of PTH Replacement Therapy in Pseudohypoparathyroidism Type 1a and 1c. J Bone Miner Res. 2021.

clinical_trial2021
4

Liu J, Chen Y, Nakamoto Y, Weinstein LS. Systematic Review and Meta-analysis of GNAS Mutation Features in Albright Hereditary Osteodystrophy and Pseudohypoparathyroidism. Bone. 2020.

meta_analysis2020

Medication Comparisons

Compare medications used to treat Pseudohypoparathyroidism Type 1c C2932716. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy